GlassScriptPhysician profile
Yung Lyou
NPI 1013277342
$63,124.39
in general payments reported to CMS, 2019-2025
51 companies · $7,637 in 2025
The $7,637 reported for 2025 was more than what 86% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $474 · 2020: $1,726 · 2021: $8,660 · 2022: $22K · 2023: $19K · 2024: $3,554 · 2025: $7,637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Consulting Fee: $6,845 · Food and Beverage: $6,251 · Honoraria: $200 · Education: $32.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,887.50 |
| Consulting Fee | $6,845.00 |
| Food and Beverage | $6,250.89 |
| Honoraria | $200.00 |
| Education | $32.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $39,878.05 | 2020-2025 | Rybrevant, Erleada, Balversa |
| Astellas Pharma US INC | $4,175.36 | 2021-2025 | Padcev, Xtandi, Xospata |
| Seagen INC. | $3,137.36 | 2019-2023 | Adcetris, Tukysa |
| Emd Serono, INC. | $2,089.14 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,947.51 | 2022-2025 | Imfinzi, Calquence, Tagrisso |
| Pfizer INC. | $1,820.32 | 2020-2025 | |
| Astellas Pharma Global Development | $1,743.00 | 2022 | |
| Aveo Pharmaceuticals, INC. | $1,722.21 | 2022-2025 | Fotivda |
| Janssen Scientific Affairs, LLC | $1,080.00 | 2025 | Rybrevant |
| Celgene Corporation | $814.15 | 2022-2025 | Reblozyl, Pomalyst |
| Merck Sharp & Dohme LLC | $505.77 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $465.74 | 2022-2025 | |
| Daiichi Sankyo INC. | $453.27 | 2023-2025 | Enhertu, Datroway |
| Abbvie INC. | $331.42 | 2023-2025 | |
| Eisai INC. | $326.02 | 2019-2025 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $285.29 | 2019-2025 | Braftovi, Mektovi, Tukysa |
| E.R. Squibb & Sons, L.L.C. | $276.40 | 2022-2025 | Opdualag, Opdivo |
| Genentech USA, INC. | $264.33 | 2019-2025 | Alecensa, Tecentriq, Itovebi |
| Lilly USA, LLC | $215.50 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Takeda Pharmaceuticals U.S.A., INC. | $173.12 | 2023-2025 | Fruzaqla, Iclusig, Ninlaro |
| Gilead Sciences, INC. | $173.06 | 2022-2025 | Trodelvy |
| Incyte Corporation | $106.58 | 2022-2024 | Jakafi, Pemazyre, Monjuvi |
| Clovis Oncology, INC. | $104.63 | 2020-2021 | |
| Amgen INC. | $102.23 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $97.92 | 2023-2025 | Libtayo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.00 | 2025 | |
| Exelixis INC. | $82.33 | 2020-2025 | Cabometyx |
| Coherus Oncology, INC. | $65.16 | 2022-2025 | Loqtorzi |
| Glaxosmithkline, LLC. | $57.51 | 2024-2025 | Ojjaara, Jemperli, Zejula |
| Jazz Pharmaceuticals INC. | $54.22 | 2025 | |
| Deciphera Pharmaceuticals INC. | $42.32 | 2024-2025 | Qinlock |
| Sobi, INC | $39.97 | 2023-2024 | |
| Caris Mpi, INC. | $39.89 | 2025 | Mi Cancer Seek |
| Pharmacyclics LLC, An Abbvie Company | $39.60 | 2023 | Imbruvica, Epkinly |
| Bayer Healthcare Pharmaceuticals INC. | $39.47 | 2022-2025 | |
| Morphosys, US INC. | $35.45 | 2022 | |
| Beone Medicines USA, INC. | $34.28 | 2025 | Brukinsa |
| Genmab U.S., INC. | $32.32 | 2023 | Epkinly |
| Karyopharm Therapeutics INC. | $28.66 | 2024 | Xpovio |
| Rigel Pharmaceuticals, INC. | $27.47 | 2023-2025 | Rezlidhia, Gavreto, Tavalisse |
| Blueprint Medicines Corporation | $25.93 | 2023 | Ayvakit |
| Tolmar, INC. | $23.49 | 2023 | |
| Taiho Oncology, INC. | $15.96 | 2025 | |
| Puma Biotechnology, INC. | $15.83 | 2024 | |
| Alexion Pharmaceuticals, INC. | $14.40 | 2025 | Ultomiris |
| Beigene USA, INC. | $13.08 | 2022 | |
| Janssen Pharmaceuticals, INC | $11.60 | 2019 | |
| Dendreon Pharmaceuticals LLC | $11.07 | 2020 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yung Lyou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.